Compare Quest Diagnostics Inc (DGX) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Liberty Global Ltd Class C — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.48B). The key difference: Quest Diagnostics Inc is far larger — about 7.5× Liberty Global Ltd Class C's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| DGX | LBTYK | |
|---|---|---|
Market Cap | $26.21B | $3.48B |
Sector | Health | Technology |
52-Week High | $238.50 | $12.67 |
52-Week Low | $173.49 | $9.59 |
Enterprise Value | $31.97B | $10.13B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
LBTYK trades at $10.105, up 1.15% on the day, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q2 2026 miss, while full-year 2025 showed a net loss of $7.14B. Positive cash flow of $264.80M in 2025 and strategic moves like the Ziggo Group spin-off planned for 2027 highlight management's focus on unlocking value. Analyst sentiment is largely bullish with 69% buy ratings, citing sum-of-the-parts potential.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside if successful, but persistent losses and competitive pressures pose risks. Investors should weigh the high analyst optimism against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
